Loading stock data…
EXEL
$48.70+4.28 (+9.64%)
After Hours$48.58-0.12 (-0.25%)· Last close May 6
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Exelixis, Inc. in the Healthcare sector is trading at $48.70. The stock is currently near its 52-week high of $49.62, remaining 16.8% above its 200-day moving average. Technical signals show neutral RSI of 66 and bullish MACD crossover, explaining why EXEL maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Overbought levels (RSI 66) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$48.70
Potential Upside
40.7%
Whystock Fair Value$68.52
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus17 analysts
Buy
Mean target$48.06-1.3%
Range$35.00 – $60.00
Fundamentals
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced r...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$11.83B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
16.76
Beta
Defensive asset. Lower volatility than the S&P 500.
0.42
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
27.87%
Volume
Today's trading volume
6.29M
Recent News
Exelixis Seen Trading Steady on Modest Drug Growth, RBC Says
Exelixis (EXEL) shares are likely to trade in line with peers as its cancer drug cabozantinib, used
EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus
EXEL beats Q1 EPS estimates on lower costs and buybacks but misses on revenues; Cabometyx sales lag estimates as pipeline progress and new buybacks stay in focus.
Exelixis, Inc. Q1 2026 Earnings Call Summary
Moby summary of Exelixis, Inc.'s Q1 2026 earnings call
Exelixis Q1 Earnings Call Highlights
Exelixis (NASDAQ:EXEL) executives highlighted continued momentum for its cabozantinib franchise and provided updates on the expanding development program for zanzalitinib during the company’s first-quarter 2026 earnings call. Cabozantinib revenue grows as Exelixis expands GI commercial footprint Pr
Exelixis (EXEL) Q1 2026 Earnings Transcript
Michael M. Morrissey, our President and CEO; Christopher J. Senner, our Chief Financial Officer; Dana T. Aftab, our Executive Vice President of Research and Development; and Patrick Joseph Haley, our Executive Vice President, Commercial, who will review our progress for the first quarter 2026 ended 03/31/2026. Key highlights for the quarter include: first, we saw continued strong performance of the cabozantinib business in 2026.